Life sciences / Interactive model
Model the science.
Fund the company.
Drug discovery startups need one connected view of program economics, development cost, operating burn, milestone timing, and capital.
Build the modelLive planning workspace
From development plan to capital plan.
Build the operating and clinical plan first. The model turns those assumptions into cash needs and a clean asset ledger for the downstream rNPV, fundraising, and cap-table tools.
Changes calculate instantly
01 / Company plan
Set the operating base.
Enter monthly company costs separately from asset development spend so the financing requirement stays explainable.
02 / Program economics
Build the asset assumptions.
03 / Cost-to-complete worksheet
Build each phase from operating drivers.
Start with a benchmark scale, then replace the planning defaults with protocol, vendor, headcount, CMC, and regulatory assumptions specific to the asset.
Editable assumptions
Phase 1 cost build
Derived cost to complete$15.1M
Activity$6.0M
Sites / vendors$0.8M
Internal team$2.0M
CMC$3.0M
Regulatory + other$1.7M
Contingency$1.6M
Clinical transition probabilities use BIO’s 2011–2020 all-indication benchmarks: Phase 1 52.0%, Phase 2 28.9%, Phase 3 57.8%, and filed 90.6%. Discovery and preclinical values are editable planning assumptions. Costs vary materially by indication, modality, trial design, geography, and sourcing strategy.
04 / Development plan
Set the phase methodology.
Cost and duration now flow directly from the worksheet. Review the derived development plan, then adjust phase transition probabilities for modality and therapeutic area.
PhaseCost to completeDurationProb. of advancing
Discovery
From cost worksheet$3.0M
From cost worksheet1 yrs
Preclinical
From cost worksheet$5.0M
From cost worksheet1.5 yrs
Phase 1
From cost worksheet$15.1M
From cost worksheet1.5 yrs
Phase 2
From cost worksheet$30.0M
From cost worksheet2 yrs
Phase 3
From cost worksheet$80.0M
From cost worksheet3 yrs
Filed
From cost worksheet$10.0M
From cost worksheet1 yrs
Method note
Each worksheet output becomes this table’s cost and duration input. Expected development cost weights future phase spend by the probability of reaching that phase; the cash plan remains conservative and schedules the full un-risked plan.
05 / Cash plan
See when capital becomes the constraint.
The model combines fixed company spend, full program costs, and the planned financing event across the selected horizon.
Operating spend Development spend
Year 1-$35.9M cash
Year 2-$46.2M cash+$60.0M raise
Year 3-$139.7M cash
Year 4-$223.1M cash
Year 5-$309.1M cash
Year 6-$385.6M cash
Annual spend and year-end cash, USD millions.
06 / Valuation handoff
Inputs ready for the rNPV ledger.
| Asset | Indication | Phase | Peak sales | Yrs to peak | Net margin | Cum. PoS |
|---|---|---|---|---|---|---|
| ABC-101Small molecule | Oncology (solid tumor) | Phase 2 | $850.0M | 4 | 32% | 15.1% |
| XYZ-202Gene therapy | Rare disease / gene therapy | Phase 1 | $420.0M | 3 | 45% | 7.9% |
| DEF-303Biologic | Immunology | Phase 3 | $1,200.0M | 5 | 30% | 52.4% |
| GHI-404Platform | Neurology | Preclinical | $300.0M | 4 | 28% | 4.7% |
Product boundary
One model flow. Clear decision gates.
This planning layer intentionally stops before asset valuation. It creates the operating and commercial assumptions; the next modules apply rNPV, financing terms, ownership dilution, and capital allocation.
Plan
Programs, phase costs, timelines, company burn, and market assumptions.
Value
Risk-adjusted asset value, scenario ranges, and portfolio value bridge.
Finance
Raise size, runway to milestones, valuation, dilution, and cap table outcomes.
Make finance useful now
Build the financial foundation
your next decision deserves.
Tell us what is changing in the business. We’ll help you identify the finance priorities that matter first.
Start a conversation